Form 4: CNS Pharmaceuticals Director Keyes Acquires Stock Options and Restricted Stock Units

Director Jeffry R. Keyes acquired stock options and restricted stock units in CNS Pharmaceuticals, Inc. related to his board service.

Summary

• On April 8, 2024, Jeffry R. Keyes, a director of CNS Pharmaceuticals, Inc., acquired 17,500 options to purchase common stock at $0.2586 per share, exercisable until April 8, 2034.
• Keyes also acquired 17,500 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
• These awards vest on the earlier of the one-year anniversary of the issuance date or the date of the 2025 annual meeting, contingent upon continued service to the company.
• Following these transactions, Keyes directly owns 62,928 shares of common stock and 80,428 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of stock options and RSUs suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The vesting of the awards is contingent upon the grantee's continued service to the Company, suggesting an expectation of ongoing involvement.

Industry Context

Stock options and restricted stock units are common forms of compensation for directors, aligning their interests with those of shareholders.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders by aligning the director's interests with theirs.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Jeffry R. Keyes, CNS Pharmaceuticals, CNSP, Stock Options, Restricted Stock Units, RSUs